We are live on
!
Find out more
EU
Emory University Portfolio holdings
AUM
$160M
1-Year Est. Return
8.57%
This Fund
S&P 500
This Quarter
Est. Return
-14.41%
1 Year Est. Return
+8.57%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$127M
AUM Growth
-$25.9M
(-17%)
Cap. Flow
-$1.77M
Cap. Flow
% of AUM
-1.39%
Top 10 Holdings %
Top 10 Hldgs %
51.19%
Holding
54
New
8
Increased
16
Reduced
16
Closed
8
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BioCryst Pharmaceuticals
BCRX
|
+$2.47M |
| 2 |
Crinetics Pharmaceuticals
CRNX
|
+$2.42M |
| 3 |
AMRN
Amarin Corp
AMRN
|
+$2.36M |
| 4 |
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
|
+$2.34M |
| 5 |
Rhythm Pharmaceuticals
RYTM
|
+$2.29M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
DBVT
DBV Technologies
DBVT
|
+$3.11M |
| 2 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$2.96M |
| 3 |
ECYT
Endocyte, Inc. Common Stock
ECYT
|
+$2.64M |
| 4 |
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
|
+$2.58M |
| 5 |
SAGE
Sage Therapeutics
SAGE
|
+$2.54M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 48.32% |
| 2 | Financials | 34.37% |
| 3 | Consumer Discretionary | 6.74% |
| 4 | Industrials | 2.63% |
| 5 | Real Estate | 1.37% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Berkshire Hathaway Class A
BRK.A
$1.09T
| $35.8M | 28.21% |
117
| – | – |
|
2
JD.com
JD
$39.6B
| $8.32M | 6.56% |
397,578
| – | – |
|
3
InflaRx
IFRX
$296M
| $2.96M | 2.33% |
81,436
-9,001
| -10% | -$277K |
|
|
RARX
4
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
| $2.71M | 2.14% |
+149,108
| New | +$2.34M |
|
|
5
Crinetics Pharmaceuticals
CRNX
$8.96B
| $2.58M | 2.03% |
+85,944
| New | +$2.42M |
|
|
GBT
6
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $2.57M | 2.03% |
62,643
+8,692
| +16% | +$326K |
|
|
7
BioCryst Pharmaceuticals
BCRX
$2.51B
| $2.56M | 2.02% |
+317,745
| New | +$2.47M |
|
|
ONC
8
BeOne Medicines Ltd
ONC
$40.3B
| $2.55M | 2.01% |
18,168
+1,526
| +9% | +$202K |
|
9
Ascendis Pharma A/S
ASND
$16.2B
| $2.46M | 1.94% |
39,217
+731
| +2% | +$45.9K |
|
10
Wave Life Sciences
WVE
$1.02B
| $2.45M | 1.93% |
58,227
+1,824
| +3% | +$81.1K |
|
|
SGEN
11
DELISTED
Seagen Inc. Common Stock
SGEN
| $2.35M | 1.85% |
41,539
+5,705
| +16% | +$358K |
|
12
Alnylam Pharmaceuticals
ALNY
$30.4B
| $2.33M | 1.84% |
31,959
+4,275
| +15% | +$329K |
|
13
Incyte
INCY
$24.4B
| $2.27M | 1.79% |
35,671
-2,966
| -8% | -$193K |
|
|
14
Rhythm Pharmaceuticals
RYTM
$7.99B
| $2.23M | 1.75% |
+82,767
| New | +$2.29M |
|
15
Iovance Biotherapeutics
IOVA
$2.95B
| $2.19M | 1.73% |
247,642
+61,727
| +33% | +$595K |
|
16
Heron Therapeutics
HRTX
$63.5M
| $2.19M | 1.72% |
84,265
+14,425
| +21% | +$397K |
|
|
ZGNX
17
DELISTED
Zogenix, Inc.
ZGNX
| $2.11M | 1.66% |
57,822
+448
| +0.8% | +$18.3K |
|
18
Travere Therapeutics
TVTX
$5.79B
| $2.1M | 1.66% |
92,940
-4,570
| -5% | -$114K |
|
|
FOLD
19
DELISTED
Amicus Therapeutics
FOLD
| $2.09M | 1.64% |
217,874
+15,148
| +7% | +$167K |
|
20
BioMarin Pharmaceuticals
BMRN
$13.3B
| $2.07M | 1.63% |
24,302
-2,638
| -10% | -$251K |
|
|
MYOV
21
DELISTED
Myovant Sciences Ltd.
MYOV
| $2.04M | 1.61% |
124,151
-2,649
| -2% | -$52.2K |
|
22
Acadia Pharmaceuticals
ACAD
$4.89B
| $1.98M | 1.56% |
122,615
-73,986
| -38% | -$1.44M |
|
|
XLRN
23
DELISTED
Acceleron Pharma
XLRN
| $1.98M | 1.56% |
+45,445
| New | +$2.27M |
|
|
GHDX
24
DELISTED
Genomic Health, Inc.
GHDX
| $1.95M | 1.54% |
30,319
-17,484
| -37% | -$1.23M |
|
25
Madrigal Pharmaceuticals
MDGL
$11.7B
| $1.92M | 1.51% |
17,038
+5,647
| +50% | +$874K |
|
Similar funds
SGCM
LCA
SMF
PCC
VCIM
RCWM
BFAG
SLG
Emory University's Q4 2018 Portfolio in Review
As of Q4 2018, Emory University held 54 positions worth $127M, down 17% from $153M the previous quarter. Its ten largest holdings account for 51% of the portfolio.
Emory University's Q4 2018 filing shows 8 new, 16 increased, 16 reduced and 8 closed positions. Its largest new stake was BioCryst Pharmaceuticals: 317,745 shares worth $2.56M. The largest sale was DBV Technologies, an estimated $3.11M.
By sector, the portfolio is most concentrated in Healthcare at 48% of assets, down from 50% a quarter earlier, followed by Financials and Consumer Discretionary.
- Emory University's largest Q4 2018 buy was BioCryst Pharmaceuticals: 317,745 shares worth $2.56M.
- Emory University added most to Madrigal Pharmaceuticals in Q4 2018, an estimated $874K increase.
- Emory University's biggest Q4 2018 reduction was Acadia Pharmaceuticals, cutting an estimated $1.44M.
- Emory University fully exited DBV Technologies in Q4 2018, selling an estimated $3.11M.
- Emory University's ten largest holdings make up 51% of its $127M portfolio in Q4 2018.
- Emory University opened 8 new positions and closed 8 in Q4 2018.
- Emory University's portfolio value fell 17% quarter-over-quarter to $127M.
Based on Emory University's 13F filing for Q4 2018, filed 12 Feb 2019.